The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Antibody Engineering
Abstract
Antibodies are unique in their high affinity and specificity for a binding partner, a quality that has made them one of the most useful molecules for biotechnology and biomedical applications. The field of antibody engineering has changed rapidly in the past 10 years, fueled by novel technologies for the in vitro isolation of antibodies from combinatorial libraries and their functional expression in bacteria. This review presents an overview of the methods available for the de novo generation of human antibodies, for engineering antibodies with increased antigen affinity, and for the production of antibody fragments. Select applications of recombinant antibodies are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 1×
“However, one class of VH chains derived from camelids, such as camels or llamas, are naturally found without a light chain, yet exhibit high antigen affinities (25).”
BackgroundReplacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728 · cited 1×
“Recently, Knappik and coworkers developed the Human Combinatorial Antibody Library (HuCal), which employs “master” frameworks representative of the human V gene subclasses and randomization of CDR3 heavy and light chain residues (102).”
BackgroundGram, H., Marconi, L. A., Barbas, C. F., Collet, T. A., Lerner, R. A., & Kang, A. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3576 · Cited by 307
de Kruif, J., Boel, E., & Logtenberg, T. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0204 · Cited by 173
Le Gall, F., Kipriyanov, S. M., Moldenhauer, G., & Little, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00713-9 · Cited by 128
Triabodies: Single chain Fv fragments without a linker form trivalent trimers
Iliades, P., Kortt, A. A., & Hudson, P. J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00475-4 · Cited by 110 · cited 1×
“Linkers greater than 15 amino acids favor the formation of monomeric scFvs, and shorter linkers between 5–12 amino acids result predominantly in the formation of dimers or diabodies, whereas joining the V H and VL regions without a linker favors the formation of trimeric species (157, 158).”
Background
Cited by
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Byrne, B., Stack, E., Gilmartin, N., & O’Kennedy, R. (2009) · Sensors · doi:10.3390/s90604407 · Cited by 422
New frontiers in nanotechnology for cancer treatment
Alexis, F., Rhee, J.-W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.017 · Cited by 347
Monoclonal TCR-redirected tumor cell killing
Liddy, N., Bossi, G., Adams, K. J., Lissina, A., Mahon, T. M., Hassan, N. J., Gavarret, J., Bianchi, F. C., Pumphrey, N. J., Ladell, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2764 · Cited by 324
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
Phase Diagrams of Quasispecies Theory with Recombination and Horizontal Gene Transfer.
Park, J.-M., & Deem, M. W. (2007) · Physical Review Letters · doi:10.1103/physrevlett.98.058101 · Cited by 69
Improved Antibody‐Specific Epitope Prediction Using AlphaFold and AbAdapt**
(2022) · doi:10.1002/cbic.202200303 · Cited by 36
Metadata
- Authors
- Maynard, J., & Georgiou, G.
- Venue
- Annual Review of Biomedical Engineering
- Publisher
- Annual Reviews
- Published
- 2000-08
- Volume
- 2
- Issue
- 1
- Pages
- 339-376
- ISSN
- 1523-9829 (ISSN-L)
- 1545-4274
- OpenAlex
- W4249881206
- Cited by
- 206
- References
- 7
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.